UGRO Capital Limited (NSE:UGROCAP)

Intra-Cellular Therapies Revenue

In the fiscal year ending March 31, 2025, UGRO Capital had annual revenue of 6.41B INR with 22.73% growth. UGRO Capital had revenue of 1.77B in the quarter ending March 31, 2025, with 9.92% growth.

• Revenue: 6.41B
• Revenue Growth: +22.73%
• P/S Ratio: 2.89
• Revenue / Employee: 3.15M
• Employees: 2,149
• Market Cap: 19.58B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2025	6.41B	1.19B	22.73%
Mar 31, 2024	5.22B	1.88B	56.18%
Mar 31, 2023	3.35B	1.89B	129.89%
Mar 31, 2022	1.46B	563.50M	63.20%
Mar 31, 2021	891.59M	79.22M	9.75%